Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study of the Impact of Rosuvastatin Administration on Residual Chronic Immune Activation Under Antiretroviral Therapy: CESAR (Crestor En Sus Des AntiRetroviraux)

Next Previous
X
Search
Trial Profile

Pilot Study of the Impact of Rosuvastatin Administration on Residual Chronic Immune Activation Under Antiretroviral Therapy: CESAR (Crestor En Sus Des AntiRetroviraux)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications HIV-1 infections
  • Focus Biomarker; Pharmacodynamics
  • Acronyms CESAR

    • Most Recent Events

    • 13 Nov 2015 Status changed from recruiting to completed based on the full analysis set results published in the JAIDS.
    • 02 Nov 2015 Primary endpoint [Receptor activation (Coexpress activation markers: proportion of peripheral CD8 T cells that co-express the activation markers CD38 and HLA-DR.)] has not been met as per the results published in the JAIDS.
    • 02 Nov 2015 Primary endpoint (CD8+ cell count ) has been met as per the results published in the JAIDS.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top